Abstract Number: 255 • 2012 ACR/ARHP Annual Meeting
Clinically Meaningful Effect of Strontium Ranelate On Knee Osteoarthritis Symptoms
Background/Purpose: In the SEKOIA study, strontium ranelate 2g/day has been demonstrated to reduce total WOMAC score, pain subscore and global knee pain assessed using a…Abstract Number: 256 • 2012 ACR/ARHP Annual Meeting
Strontium Ranelate Decreases the Level of Urinary CTX-II in Patients with Knee Osteoarthritis
Background/Purpose: Knee osteoarthritis is a chronic disease affecting the global joint and characterized by cartilage degradation as well as subchondral bone remodelling. Effects of strontium…Abstract Number: 257 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Four 12-Week Phase III Clinical Trials Investigating the Effect of TDT 064, a Transdermal Gel, in Osteoarthritis of the Knee
Background/Purpose: A transfersome is an ultradeformable lipid vesicle originally developed to deliver high concentrations of drug (eg NSAIDs) transdermally. Large interventional trials in osteoarthritis (OA)…Abstract Number: 258 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of the Chinese Herbal Compound Hou-Lou-Xiao-Ling Dan in Patients with Osteoarthritis of the Knee: Results of a Phase II International Study
Background/Purpose: Traditional Chinese Medicine (TCM), which includes the use of herbal medicines, is widely used to treat osteoarthritis (OA) of the knee in Asian societies;…Abstract Number: 259 • 2012 ACR/ARHP Annual Meeting
Long-Term Tanezumab Treatment for Osteoarthritis: Efficacy and Safety Results
Background/Purpose: Nerve growth factor (NGF) levels are associated with increased pain perception and are elevated in joints of arthritis patients. Tanezumab, a humanized monoclonal antibody,…Abstract Number: 260 • 2012 ACR/ARHP Annual Meeting
Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program
Background/Purpose: Tanezumab (TNZ) has been shown to be efficacious for pain and function in patients with hip and knee osteoarthritis (OA). Unexpected reports of adverse…Abstract Number: 261 • 2012 ACR/ARHP Annual Meeting
Effect of Advancing Age On the Gastrointestinal Safety of Celecoxib Versus Nonselective Nonsteroidal Anti-Inflammatory Drugs: A Post Hoc Analysis of GI-Reasons
Background/Purpose: Celecoxib use was associated with a lower risk of clinically relevant upper and lower GI events than nonselective (ns)NSAIDs in patients (≥ 55 years)…Abstract Number: 262 • 2012 ACR/ARHP Annual Meeting
Flexible Footwear Reduces Dynamic Joint Loads in Knee Osteoarthritis: Results of a 6 Month Randomized Controlled Trial
Background/Purpose: Dynamic joint loads are important in the pathophysiology of knee OA and biomechanical interventions aim to reduce these loads in hopes of improving symptoms…Abstract Number: 263 • 2012 ACR/ARHP Annual Meeting
Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac: A Systematic Review of the Literature and Meta-Analysis
Background/Purpose : The management of mild-to-moderate pain has traditionally been based on the use of non-steroidal anti-inflammatory drugs (NSAIDs) and the synthetic non-opioid analgesic paracetamol…Abstract Number: 264 • 2012 ACR/ARHP Annual Meeting
Specialized Footwear Decreases Medial Tibial Bone Mineral Density Over 48 Weeks in Knee Osteoarthritis
Background/Purpose: Osteoarthritis (OA) is characterized by increased subchondral bone mineral density at affected joints. In the knee, proximal tibial bone mineral density (BMD) is…Abstract Number: 265 • 2012 ACR/ARHP Annual Meeting
Reducing Loads in the Contralateral Side in Medial Knee Osteoarthritis; A 3-Year Follow-up Study
Background/Purpose: No strategies have been shown to prevent Medial knee osteoarthritis (MKOA). For those with symptomatic unilateral MKOA, the contralateral knee may be at risk…Abstract Number: 266 • 2012 ACR/ARHP Annual Meeting
Knee Joint Stabilization Therapy in Patients with Osteoarthritis of the Knee: A Randomized, Controlled Trial
Background/Purpose: Patients with knee osteoarthritis (OA) and instability of the knee joint may not benefit optimally from regular strengthening training. Therefore, we evaluated the effectiveness of a newly…Abstract Number: 227 • 2012 ACR/ARHP Annual Meeting
Long Term Outcome of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies and Amyopathic Dermatomyositis
Background/Purpose: The aim of this study was to assess the long term clinical course and outcome of interstitial lung disease (ILD) in polymyositis/dermatomyositis (PM/DM) and…Abstract Number: 228 • 2012 ACR/ARHP Annual Meeting
Simultaneous Initiating of Glucocorticoids and disease-Modifying Antirheumatic Drug Therapy in Polymyositis and Dermatomyositis Patients Results in the Opportunity to Taper Dosage of Glucocorticoids Early
Background/Purpose: Glucocorticoids are the cornerstone of therapy in patients with polymyositis (PM) and dermatomyositis (DM). However, side effects are common. Furthermore, glucocorticoids exhibits an…Abstract Number: 229 • 2012 ACR/ARHP Annual Meeting
Clinical Differences Between Adult and Juvenile Dermatomyositis Associated with Anti-NXP2 Autoantibodies
Background/Purpose: Myositis specific antibodies (MSA) can divide dermatomyositis patients into distinct clinical subsets and help predict the risk of disease complications such as interstitial lung…
ACR Meeting Abstracts